Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis
This study supports the cost-effectiveness of using sintilimab in combination with chemotherapy. Nevertheless, the cost-effectiveness of combining sintilimab with IBI305 and chemotherapy in this particular patient group may be lacking.
Authors
- Huiling Xu (ORCID: https://orcid.org/0000-0001-8195-8648)
- Qiao Liu (ORCID: https://orcid.org/0000-0001-8739-6236)
- Juan Peng
Institutions
- Central South University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Jiangxi Provincial People's Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1371/journal.pone.0312133
- Citations
- 2
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.78